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ABSTRACT: GPCR subtypes possess distinct functional and
pharmacological profiles, and thus development of subtype-
selective ligands has immense therapeutic potential. This is
especially the case for the angiotensin receptor subtypes AT1R
and AT2R, where a functional negative control has been
described and AT2R activation highlighted as an important
cancer drug target. We describe a strategy to fine-tune ligand
selectivity for the AT2R/AT1R subtypes through electronic
control of ligand aromatic-prolyl interactions. Through this
strategy an AT2R high affinity (Ki = 3 nM) agonist analogue that exerted 18,000-fold higher selectivity for AT2R versus AT1R
was obtained. We show that this compound is a negative regulator of AT1R signaling since it is able to inhibit MCF-7 breast
carcinoma cellular proliferation in the low nanomolar range.
G-protein-coupled receptors (GPCRs) orchestrate most
cellular responses to neurotransmitters and hormones.1 They
form a major therapeutic platform for an array of diseases, with
50% of clinically marketed drugs targeting this receptor family.2
GPCR subtypes within a subfamily usually possess distinct
functional and pharmacological profiles,3 and thus development
of subtype-selective ligands has immense untapped therapeutic
potential. This is clearly evident for two of the Angiotensin II
(AII) receptor subtypes, AT1R and AT2R. Although they are
recognized with similar affinity by the hormone AII (NH2-
DRVYIHPF-OH),4,5 the effects of AT2R activation (vaso-
dilation, apoptosis, and antiproliferation) antagonize those
mediated by AT1R (cellular growth and proliferation for
AT1).6,7 Since AT2R stimulation has been implicated in tumor
suppression,8,9 tissue repair and regeneration, this receptor has
been assigned as an important pharmaceutical drug tar-
get.8,10−13 Therefore, a fine-tuning of the different functional
responses of AT1R and AT2R by the use of receptor subtype-
selective ligands could be a powerful therapeutic tool.12
However, significant challenges are posed for the rational
design of GPCR subtype-selective ligands due to the high
sequence conservation within the receptor subfamily.3 Indeed,
in the absence of detailed knowledge of ligand−receptor
recognition interactions for AT2R, identification of AT2R-
selective ligands came after long and delicate synthetic
efforts.10,14 Here, we describe a strategy to fine-tune ligand
selectivity for the AT2R/AT1R subtypes through electronic
control of ligand aromatic-prolyl interactions (Figure 1). On
the basis of this strategy, a highly AT2R-selective (18,000-fold
higher selectivity (IC50AT1R/IC50AT2R)) and high affinity
agonist analogue (Ki = 3 nM) that exerted antiproliferative
activity against MCF-7 breast carcinoma cells was obtained,
pointing to a rational way to generate highly receptor subtype-
selective drugs.
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Engineering the Hormone AII To Be Selective for
AT2R. Recent exciting advances in the field of GPCR structural
biology have provided unprecedented insights into the GPCR
fold and the ligand binding pocket architecture.1 This
knowledge has allowed the generation of models for the
AT1R bound to AII.15−17 AII binds to the two receptors with
similar affinity (KdAT1R = 1.8 nM, KdAT2R = 2.3 nM;
Supplementary Table S3). To guide the design of subtype-
selective ligands for AT2R/AT1R, we constructed the receptor
models bound to AII and screened for potential hotspot areas
that could be discriminative between the two receptor subtypes
(Figure 1). AT2R and AT1R are characterized by a sequence
identity of 36.5% and similarity of 56.7% (see also full sequence
alignment, Supplementary Figure S1). Even higher identity
(40.4%) and similarity (60.1%) are observed in the trans-
membrane region, where a large portion of the ligand binds.
Although in our model AII was embedded in a receptor area
with high conservation in both receptors (gray stick and
surface, Figure 1b), a diverse region was located at the
extracellular loop 2 (ECL2) (red stick, Figure 1b) and the
orthosteric pocket (top of TM5 and middle of TM6) that could
serve as a ligand-receptor subtype selectivity region. At this
point, one has to bear in mind that the ECL2 is a very flexible
region and therefore challenging to model. From our model
and in accordance with literature data,15,16 it was pinpointed
that the C-terminus of AII, which carries a Pro at position 7
followed by Phe (Figure 1c,b), penetrates deeper into the
receptor ligand binding site.
Exploring these unconserved receptor regions revealed the
presence of more hydrophobic and larger residues that limit the
binding pocket of AT2R relative to AT1R in our obtained
structural models (VAT2R 1694 Å3 < VAT1R 1825 Å3; for
calculation see Supporting Information). It could thus follow
that a more hydrophobic and compact motif that exploits this
receptor region should be sought for an analogue to be selective
for AT2R. Similar observations on the ligand-receptor subtype
selectivity were highlighted for other GPCR families such as the
nociceptin δ-OR receptors: although presenting high residue
conservation on their ligand binding site, ligand selectivity for
those receptors was based on a few critical alterations of smaller
to larger residues.19 However, ligand selectivity for β-adrenergic
receptor (AR) subtypes was assigned to polar residue
alteration.20
We postulated that an electronic strategy18,21 could be
adopted in the C-terminus of AII, where Pro7 is located, to
control and tune the compactness of the C-terminus of AII
analogues and thus their receptor subtype selectivity (Figure
1c−e). According to this strategy, an aromatic-prolyl
interaction can be stabilized by a C−H/π interaction, where
the aromatic ring donates electron density (π-electron donor)
to the electron-deficient C−H bonds of the pyrrolidine ring.18
Therefore, electron-rich aromatic residues, shaped after
appropriate positioning of an electron-donating group (such
as -OH) at the 4-X position of an aromatic ring, preceding a
proline, should have the potential to stabilize the aromatic-
prolyl interaction (Figure 1d). Thus, this interaction should
lead to a more compact conformation for the specific residues
and high selectivity for the AT2R. In contrast, electron-deficient
aromatic residues, created after installing an electron-with-
drawing group (i.e., NO2) at the 4-X position of an aromatic
ring, followed by a proline, should lead to less favorable
interactions and thus lower compactness and lower selectivity
for AT2R (Figure 1e). Thus, we hypothesized that appropriate
manipulation/tuning of the electronics of an aromatic ring
(position 6 of AII) adjacent to a proline ring (position 7 of AII)
could result in a delicate electronic control/tuning of C−H/π
interactions and thus regulation of GPCR-ligand subtype
selectivity.
To test the validity of this hypothesis, we synthesized AII
analogues, substituting the His at position 6 of the AII with 4-
substituted phenylalanine with electron-rich (-OH), electron-
neutral (-H and -OPO3H2), and electron-deficient (-NO2)
groups. To monitor the compactness of the synthesized
molecules, we used as an internal sensor the NMR derived %
cis character of the Aro6−Pro7 amide bond, since it has been
established that the strength of the aro-pro compactness follows
a positive correlation with the cis isomerization state of the
aromatic-prolyl amide bond.18 The 4-NO2-phenylalanine AII
analogue, an electron-deficient aromatic residue (Hammett
substituent constant σpara = 0.78), should mostly disfavor the
aro-pro interaction and present a minor cis conformation,
whereas phenylalanine and phospho-tyrosine (σpara ≈ 0.00 and
0.26, respectively) should generate moderate compactness and
cis conformation. Finally, tyrosine, an electron-rich aromatic
residue (σpara ≈ −0.37), should favor aro-pro compactness.
Supporting this hypothesis, our NMR data indicated that
electron-rich residues favored the aromatic-prolyl interaction
and the cis amide bonds, with the following ranking order of
aromatic substituents: −-OH > -H ≈ -OPO3H2 > -NO2 (the %
cis was found to be 40%, 20%, 25%, and 5%, respectively).
Figure 1. 3D model of the AII−AT1R complex and the electronic
tuning strategy used in this work for AII. (a) Key interactions between
the hormone AII (yellow stick and surface) and AT1R (gray stick),
comprising hydrogen bonds (red dashed line) and hydrophobic
contacts (green dashed line). (b) Conserved regions between AT1R
and AT2R depicted in gray stick and surface; unconserved regions are
highlighted in a red stick representation. ECL1, ECL2 correspond to
the extracellular loops 1 and 2 and TM2, 4, 5, and 6 correspond to
transmembrane regions 2, 4, 5, and 6, respectively. (c) The sequence
of the hormone AII with its C-terminus highlighted. (d,e) The H6 of
AII was altered in this work with 4-X substituted phenylalanine on the
frame of an electronic strategy to regulate the compactness of the AII
C-terminus. In (d) electron-rich aromatic residues stabilize the
aromatic-prolyl interactions and lead to compactness,18 and in (e)
electron-deficient aromatic residues result in less favorable aromatic-
prolyl interactions and relatively reduced compactness.
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[Y]6-AII Shows Enhanced cis Isomerization and
Aromatic-Prolyl Compactness in Solution. To further
probe the [Y]6-AII analogue structure in solution we used
NMR. A selected region of the 1H−1H 2D NOESY spectrum of
the analogue is shown in Figure 2. Interestingly, in aqueous
solution [Y]6-AII showed two distinct sets of proton resonances
that correspond to discrete cis and trans conformational
populations. This was in contrast to the native AII where a
single set of peaks was observed, representing the single
conformer (trans) (Supplementary Figure S2−S4). This
structural plasticity (coexistence of nearly equal populations
in solution of two different discrete conformations) could be
favorable for recognition selectivity. Due to excellent dispersion
of the resonances of the cis and trans conformers,
deconvolution and complete resonance assignment was
achieved (Supplementary Tables S1 and S2). Structure
calculations for the distinctive cis and trans isomers were
performed, and the structural origin of the stabilization of the
relevant conformational potencies was mapped (Figure 2). As
was expected, for the [Y]6-AII cis isomer the calculations
produced a family of structures with the aromatic rings of Tyr6
and Phe8 stacked around the Pro7 ring, thus leading to a
compact hydrophobic motif (Figure 2b). The structural
architecture of this motif was found to mimic closely the
conformation adopted by Tyr-Pro-Phe minicores recorded in
the crystallographic protein database (Supplementary Figure
S5). The compactness of the cis over the trans form was also
probed through a more reduced accessibility of the peptide
bonds as determined from both the amide proton temperature
coefficients and translational diffusion values (i.e., for Tyr4 we
determined a diffusion coefficient of 1.9 × 10−10 m2 s−1 for the
cis and 2.3 × 10−10 m2 s−1 for the trans, Supplementary Figure
S6).
[Y]6-AII Analogue Is Selective for AT2R. Since the [Y]6-
AII analogue experimentally fulfilled the selectivity criteria for
AT2R hypothesized at the onset of this study, we measured its
binding to AT1R and AT2R recombinantly expressed in
mammalian cells. Interestingly, the analogue ligated AT2R with
high affinity (Ki = 3.4 ± 0.8 nM), whereas saturable binding to
AT1R was in the submillimolar range (Supplementary Table
S3). In order to elucidate whether the [Y]6-AII AT2R subtype
selectivity was due to the effectiveness of the electronic tuning
of the aromatic-prolyl interaction, we then performed binding
experiments of the rest of the analogues to the AT1R and
AT2R (Figure 3, Supplementary Tables S4 and S5). Notably,
the AT2R/AT1R fold selectivity of all the AII analogues was
directly correlated to the aro-pro compactness of the analogues
as described above (Figure 3, Supplementary Table S5): the
[Y]6-AII analogue presented a 18,000-fold higher selectivity
(IC50AT1R/IC50AT2R); [4-OPO3H2-F]
6-AII and [F]6-AII
showed similar receptor subtype selectivities (4479 and 4786,
respectively). In contrast and as expected, [4-NO2-F]
6-AII
presented a much lower (26-fold less) selectivity for the AT2R/
AT1R receptor subtypes (694).
Potential Localization of the [Y]6-AII Analogue in the
AT2 Receptor: Modeling and Functional Data. In order to
assess the origin of the highest selectivity of the [Y]6-AII
analogue to the AT2R over the AT1R, the relevant analogue
was docked into the two receptors (Figure 4). Residues that
interact with the [Y]6-AII analogue in both receptors
(Supplementary Figure S7) are also listed in Supplementary
Table S6 containing their residue ID as well as the
corresponding Ballesteros-Weinstein numbering.22
[Y]6-AII adopted a more compact and stacked conformation
in the Tyr6-Pro7-Phe8 region, as well as a slightly deeper
penetration into the binding pocket of AT2R with respect to
Figure 2. (a) Selected region of a 350 ms NOESY spectrum of [Y]6-
AII (90% H2O/10% D2O). The red and green lines denote the NOE
connectivities for the trans and cis isomers, respectively. Solution
structures of the distinctive cis (b) and trans (c) conformers of the
engineered AII analogue.
Figure 3. (a) Competition binding assays of [Y]6-AII analogue to
AT1R, AT2R wild type, and mutants: AT1R, open circle; wild type
AT2R, black circles; AT2R-Y189A, blue diamonds; AT2R-Y189N,
green triangle; AT2R-F272(6.51)A, red square; AT2R-F272(6.51)H,
orange triangle. Kd and Ki values are given in Supplementary Table S3.
(b,c) Plots of fold selectivity values for the two AII receptor subtypes
(IC50(AT1R)/IC50(AT2R)]) versus % of cis (b) and the value of
Hammet substituent constants σpara (c) for the different AII analogues
(see also Supplementary Table S5). (d) PC12W cells, either
transduced with the Ad-AT2R or untransduced, were used for the
evaluation of the AT2R agonistic effect of [Y]6-AII in the presence of
either 1 nM AII or [Y]6-AII. Agonist-induced neurite outgrowth by AII
or [Y]6-AII for 24 h stimulation was quantified by counting neurite-
positive cell numbers in five randomly selected photos/well. The
neurite outgrowth-positive cells were defined as the cells with neurite
length longer than their cell diameters. This experiment was carried
out in triplicate and repeated twice.
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AT1R (see also Supplementary Figure S8). To this contributed
unconserved regions between the two receptors that were
mainly mapped in TM5 (top region) and the ECL2 region.
On the other hand, unconserved residues in the ECL2 of
AT2R (red stick and surface, Figure 4) and in particular the
aromatic Y189 that contributes to the formation of a
hydrophobic groove that favorably accommodated V3 of [Y]6-
AII seem to push the analogue deeper in the transmembrane
region of the AT2R to develop the favorable F8 ([Y]6-AII)−
F272(6.51) (AT2R) stacking interaction (the Ballesteros-Wein-
stein numbering22 of F272 is shown in parentheses). Y189 and
F272(6.51) of AT2R, which seem to develop the aforementioned
favorable interactions with the N- and C-termini of [Y]6-AII,
are altered to N174 and H256(6.51), respectively, in AT1R. In
order to verify that, among others, these residues are also
responsible for the [Y]6-AII affinity and selectivity to AT2R/
AT1R, we made the following AT2R mutants: Y189A, Y189N,
F6.51A, and F272(6.51)H. These changes introduced in AT2R
polar residues or residues of smaller size near the ligand binding
pocket, thus emulating the environment in the AT1R ligand
binding pocket. Both AII and [Y]6-AII were used to probe the
binding pocket of AT2R and its variants. The affinity of AII,
which has histidine at position 6, was not altered for the AT2R
mutants with respect to the wild type receptor. It was
interesting to note that the affinity of AII was slightly higher
for the AT2R mutants emulating the environment in the AT1R
(Y189N and F272(6.51)H) compared to the Y189A and F272(6.51)
AT2R variants (Supplementary Table S3). However, [Y]6-AII
presented a largely reduced affinity for the AT2R variants by a
factor of 4 to 5 folds with respect to the wild type receptor
(Supplementary Table S3). Overall, these data support the
initial hypothesis that the [Y]6-AII superior selectivity to AT2R
is based on a more hydrophobic and compact binding pocket
(compared to AT1R).
[Y]6-AII Analogue Is an AT2R Agonist and a Negative
Regulator of AT1R Signaling. To evaluate if the tight binder
and subtype AT2R-selective [Y]6-AII analogue could serve as a
desired AT2R agonist, we monitored its effect on cell
differentiation (neurite outgrowth) in AT2R-overexpressing
PC12W cells. PC12W cells have been shown to be capable of
expressing AT2R in lengthy serum-free culture conditions,23
and their neurite outgrowth is stimulated by AII.24 As shown in
Figure 3d, both AII and the [Y]6-AII analogue significantly
stimulated neurite outgrowth in the AT2R transduced cells.
This phenotype was ligand dose-dependent in the range of 1
pM to 100 nM for both AII and [Y]6-AII.
A functional negative crosstalk among AT2R and AT1R has
been extensively described in several pathophysiological
conditions including cancer,25,26 evidencing AT2R activation
as an important cancer drug target.8,9,27 To probe the efficacy of
our AT2R-selective [Y]6-AII agonist to act as a negative
regulator of AT1R signaling, we focused on MCF-7 breast
carcinoma cells where both AT1R and AT2R are expressed28
and native AII stimulates cellular proliferation through AT1R
binding.28 We assessed the effect of [Y]6-AII in MCF-7 cell
proliferation by growth curves comparing [Y]6-AII-treated cells
with vehicle-treated control cells (Supplementary Figure S11).
As was expected, [Y]6-AII efficiently inhibited MCF-7
proliferation at concentrations of 10−8 M and showed evidence
of antiproliferative effects at 10−9 M (IC50 of ∼5 × 10−8 M).
Here, we demonstrated that AII receptor subtype selectivity
could be precisely sculpted by tuning the electronic character of
a simple substitution of the hydrogen in the para-position of
phenylalanine introduced at position 6 of AII (4-x-Phe6).
Specifically, the [Y]6-AII analogue with an electron-donating
group (-OH) resulted in a selective and high affinity binder for
AT2R (Ki = 3.4 ± 0.8 nM), whereas electron-withdrawing
groups diminished high selectivity for this receptor subtype.
Most importantly, this receptor recognition phenotype is
directly correlated to the compactness of the 4-X-Phe6-Pro7-
Phe8 motif induced by this electronic control. AII analogues
containing electron-deficient aromatic residues at position 6
presented reduced selectivity for the AT2 receptor in contrast
to electron-rich aromatic residues. For instance, [4-NO2-F]
6-
AII displayed 26 times lower AT2R selectivity in comparison to
[Y]6-AII, but low micromolar affinity for AT1R. Along the same
line, [F]6-AII presented almost 4 times lower selectivity for
AT2R in comparison to the [Y]6-AII analogue. This is the first
time that a strategy is described to control ligand-receptor
subtype selectivity via delicate tuning of aromatic electronics.
This strategy could be potentially adapted to other peptidergic
GPCR subtypes where the ligand encompasses a proline or an
aromatic-proline motif (i.e., see Supplementary Table S7).
Indeed, we were intrigued to indirectly validate the strength of
this methodology through uncovering a correlation of ligand
stereoelectronic control with receptor subtype specificity for
the Proteolytically Activated PAR1 and PAR4 receptor
subtypes.29 Although authors of this study had not originally
pinpointed the stereoelectronic significance of 4-X-Phe
substitution in their strategy to design PAR1/PAR4 selective
ligands, they used 4-substituted phenylalanine at position 2 of
the GYPGKF native sequence, which carries an electron-rich
(-OH), with electron-neutral (-H), and electron-deficient (-F)
groups, and produced analogues conferring PAR4 selectivity,
no receptor subtype selectivity, and higher PAR1 selectivity,
respectively (Supplementary Table S8).
The selective, high affinity, and equipped with discrete
conformational plasticity AT2R analogue [Y]6-AII (we name it
AGT2AG), derived in the frame of this strategy, stimulates the
activity of AT2R in PC12W cells and also inhibits MCF-7
breast carcinoma cellular proliferation. In vivo experiments are
currently underway to test the potential of [Y]6-AII as a
negative regulator in the growth of breast and pancreatic
carcinoma cells through AT2R signaling.
■ METHODS
For methods see Supporting Information.
Figure 4. Structure of [Y]6-AII in complex with AT1R (a) and AT2R
(b). [Y]6-AII is shown in yellow stick and surface, and unconserved
regions in AT1R and AT2R are shown in red stick and surfaces. Red
dashed lines correspond to hydrogen bonds, and green dashed lines to
hydrophobic contacts. Residues depicted in blue stick were mutated
for validation of the binding mode.
ACS Chemical Biology Letters
dx.doi.org/10.1021/cb500063y | ACS Chem. Biol. 2014, 9, 1420−14251423
■ ASSOCIATED CONTENT
*S Supporting Information
Methods and supplementary tables and figures. This material is
available free of charge via the Internet at http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: agtzakos@gmail.com.
Present Address
○Biological Crystallography Lab, Department of Biology and
Biotechnology, University of Pavia, Italy.
Notes
Patent WO2013/091883A2 regarding the experimental data
described here has been filed.
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
This work was supported by a MRC Career Development
Fellowship (F.M.). This research has been cofinanced by the
European Union (European Social Fund, ESF) and Greek
national funds through the Operational Program “Education
and Lifelong Learning” of the National Strategic Reference
Framework (NSRF) Research Funding Program: ARISTEIA II
(5199, SPEED to A.G.T.), Investing in knowledge society
through the European Social Fund, and also grants from the
Heart Foundation of Australia (G09M4521 and G11M5797,
awarded to R.E.W.) and Kansas Bioscience Authority
collaborative cancer research grant (M.T.). J.S. acknowledges
support from the Instituto de Salud Carlos III FEDER (CP12/
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